Quetiapine inhibits the oxidative phosphorylation in head and neck squamous cell carcinoma through suppressing NAT10-mediated ac4C modification

Read full text Summarise with VIRAT
Authors: Shanshan Du, Min Mao, Wanfen Wang, Xiaoming Xu, Shuang Ye, Longchuan Xie
Cited by: 0
References: 44

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Background: N4-acetylcytidine (ac4C) is an RNA epigenetic modification, newly discovered to be catalyzed by the enzyme N-acetyltransferase 10 (NAT10). This study aimed to elucidate the functional role and regulatory mechanism of NAT10-mediated ac4C RNA modification in head and neck squamous cell carcinoma (HNSCC), and to explore its potential as a druggable target. Methods: experiments, including binding assays, functional phenotyping (proliferation, migration, and apoptosis), and assessment of mitochondrial function via oxygen consumption rate (OCR) measurements. Results: experiments confirmed that quetiapine directly bound to NAT10, inhibited its expression, and reduced global ac4C levels. Quetiapine treatment potently suppressed HNSCC cell proliferation and migration, while promoting apoptosis. Mechanistically, quetiapine-mediated NAT10 inhibition downregulated key OXPHOS components and substantially decreased cellular OCR, indicating impaired mitochondrial respiration. Conclusions: NAT10 functions as a critical oncoprotein in HNSCC, potentially by enhancing OXPHOS-driven energy metabolism. The repurposed drug quetiapine suppresses tumor growth by targeting the NAT10/ac4C axis and disrupting mitochondrial respiratory function, positioning it as a promising therapeutic agent for HNSCC.

Fields of Study & Subjects

RNA modifications and cancer Cancer Hypoxia and Metabolism Epigenetics and DNA Methylation

Publication details

Journal / source
Translational Cancer Research
Volume
15
Issue
3
Pages
175–175
Publication date
1 March 2026
Language
EN